このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Open-label, Single-arm Trial of Ganaxolone in CDD Patients 6 Months to Less Than 2 Years Old

2026年10月30日 更新者:Immedica Pharma AB

An Open-label, Single-arm, 52-week, Multicenter Phase 3 Trial to Assess Pharmacokinetics, Safety, Tolerability, and Activity of Adjunctive Ganaxolone for the Treatment of Seizures Associated With Genetically Confirmed Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) in Pediatric Patients From 6 Months to Less Than 2 Years of Age

The goal of this clinical trial is to learn how patients with CDKL-5 deficiency disorder (CDD) aged 6 months to 2 years of age respond to treatment with ganaxolone. The main questions the trial aims to answer are:

  • The amount of the medicine that was in participants' bodies and the safety of the medicine.
  • Does the medicine ganaxolone lower the number of seizures when used in addition to the participant's usual anti-seizure treatment.

Participants will:

Take ganaxolone 3 times daily for up to 52 weeks. Visit the clinic every 3 to 5 weeks for the initial 17 weeks of the trial and thereafter every 11 to 12 weeks.

The participant's caregiver will:

Keep a daily diary of the participants seizures and use of anti-seizure medications, including the trial drug ganaxolone.

調査の概要

状態

まだ募集していません

介入・治療

詳細な説明

This is an open-label, single-arm, 52-week, multicenter trial of adjunctive ganaxolone treatment in participants 6 months to less than 2 years of age with genetically confirmed CDD. The trial consists of an up to 2-week Screening Period, 4-week prospective Baseline Period, followed by 2 parts: Part A; a 17-week ganaxolone treatment phase (including 4 to 5 weeks of ganaxolone titration followed by 12 to 13 weeks of dose maintenance) and Part B; a 35-week ganaxolone maintenance phase, and a 2-week taper period at the end of the trial. Tapering will not apply for participants continuing ganaxolone treatment after the trial.

The Screening Period will follow the Screening Visit to ensure caregivers can classify seizures and comply with completion instructions of an electronic seizure and medication diary. This will be followed by a 4-week prospective Baseline Period to assess seizure frequency for trial eligibility.

Up to 15 participants will be enrolled to ensure at least 12 participants are evaluable for the primary PK endpoints at the end of Part A of the trial, including at least 3 participants experiencing uncontrolled seizures despite treatment with at least 2 anti-seizure medications.

Participants will be monitored at Baseline and at specified visits to assess the exposure, safety and tolerability and activity of ganaxolone. PK samples will be collected at specified timepoints up until completion of Part A.

Clinical laboratory testing will be performed at local laboratories at participating sites.

研究の種類

介入

入学 (推定)

12

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

6ヶ月~2年 (子)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Key Inclusion Criteria:

  1. A diagnosis of CDD, including molecular confirmation of a pathogenic or likely pathogenic CDKL5 variant.

  2. Male or female participants aged 6 months to less than 2 years at the Baseline Visit.

  3. Failure to control seizures despite appropriate use of 1 or more anti-seizure medications at therapeutic doses. At least 3 participants will be included who failed to control seizures despite appropriate use of at least 2 anti-seizure medications.

  4. Participants will have refractory seizures with a history of at least 8 countable seizures of primary seizure types during the 28 days prospective Baseline Period prior to the Baseline Visit. Primary seizure types are seizures with or without impairment of consciousness with a clear motor component, including generalized tonic-clonic, focal to bilateral tonic-clonic, atonic/drop, bilateral clonic, bilateral tonic (sustained motor activity ≥ 3 seconds). Clusters of uncountable seizures will be counted as a single seizure.

    1. Primary seizures exclude epileptic spasms. Patients with epileptic spasms are eligible for enrolment but epileptic spasms will not be counted as qualifying countable seizures for eligibility. Epileptic spasms should not constitute the dominant seizure type during the Baseline Period.
    2. Primary seizures exclude myoclonic, absence, generalized non-motor seizures, and focal motor or non-motor seizures with or without impairment of awareness.
  5. Participants should be receiving a stable regimen of anti-seizure medications at Screening through to the end of the 4-week prospective Baseline Period and have no foreseeable change for the duration of Part A.

    1. Concurrent use of adrenocorticotropic hormone, prednisone, other glucocorticoids, or vigabatrin are permitted.
    2. Vagus nerve stimulator (VNS) settings, ketogenic diet, or a modified Atkins diet should be unchanged for 1 month prior to the Screening Visit, throughout the Screening Period and the 4-week prospective Baseline Period and without foreseeable change for the duration of Part A at the time of the Baseline Visit.
  6. Parent/caregiver is able and willing to maintain an accurate and complete daily seizure diary for the duration of the trial.

Key Exclusion Criteria:

  1. Have an active CNS infection, demyelinating disease, degenerative neurological disease, or CNS disease deemed progressive as evaluated by brain imaging (magnetic resonance imaging).
  2. Have any disease or condition (medical or surgical; other than CDKL5 deficiency) that might compromise the hematologic, cardiovascular, pulmonary, renal, gastrointestinal, or hepatic systems; or other conditions that might interfere with the absorption, distribution, metabolism, or excretion of the investigational product or would place the participant at increased risk.
  3. History of or present AST (aspartate aminotransferase/serum glutamic-oxaloacetic transaminase) or ALT (alanine aminotransferase/serum glutamic-pyruvic transaminase) >3 times the upper limit of normal (ULN) at Baseline and confirmed by a repeat testing.
  4. History of or present total bilirubin levels greater than the ULN at trial Baseline and confirmed by a repeat testing. In cases of a documented, stable medical condition (i.e., Gilbert's Syndrome) resulting in levels of total bilirubin greater than the ULN, the Medical Monitor will determine if an exception can be made.
  5. Participants with significant renal insufficiency, with an estimated glomerular filtration rate (eGFR) <30 mL/min (calculated using the Cockcroft-Gault formula or Pediatric eGFR calculator or Bedside Schwartz).
  6. Regular use of St. John's Wort or strong CYP3A4 inducers, e.g., phenytoin, carbamazepine or phenobarbital (N.B. phenytoin and phenobarbital are permitted as rescue medication on as-need basis but are not permitted as continuous maintenance medication).
  7. Have been exposed to any other investigational drug within 30 days or less than its 5 half-lives prior to the Screening Visit.
  8. Previous treatment with ganaxolone.
  9. Participation in any other trial involving administration of an investigational medication or device.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Ganaxolone

Ganaxolone sodium benzoate-free oral suspension 50 mg/ml

Ganaxolone

他の名前:
  • 活性薬物
  • Ztalmy

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Ganaxolone exposure in participants receiving ganaxolone doses up to 63 mg/kg/day
時間枠:Baseline through 17 weeks

Pharmacokinetic (PK) exposure parameter derived from population PK modelling and simulation: steady-state maximum concentration (Cmax,ss)

Baseline through 17 weeks
Ganaxolone exposure in participants receiving ganaxolone doses up to 63 mg/kg/day
時間枠:Baseline through 17 weeks

PK exposure parameter derived from population PK modelling and simulation: trough concentration (Ctrough)

Baseline through 17 weeks
Ganaxolone exposure in participants receiving ganaxolone doses up to 63 mg/kg/day
時間枠:Baseline through 17 weeks

PK exposure parameter derived from population PK modelling and simulation: systemic exposure (Caverage,ss derived as AUC over a dosing interval / tau)

Baseline through 17 weeks
Safety and tolerability of ganaxolone as adjunctive therapy for the treatment of seizures in participants receiving ganaxolone doses up to 63 mg/kg/day
時間枠:Baseline through to 52 weeks

Frequency, type, and severity of adverse events (AEs)

Baseline through to 52 weeks

二次結果の測定

結果測定
メジャーの説明
時間枠
Ganaxolone PK parameters at steady-state in participants receiving ganaxolone doses up to 63 mg/kg/day.
時間枠:Baseline through to 17 weeks

Non-compartmental-like steady-state PK parameters derived from population PK modelling and simulation: steady-state time to maximum concentration (tmax,ss)

Baseline through to 17 weeks
Ganaxolone PK parameters at steady-state in participants receiving ganaxolone doses up to 63 mg/kg/day.
時間枠:Baseline through to 17 weeks

Non-compartmental-like steady-state PK parameters derived from population PK modelling and simulation: exposure accumulation ratios

Baseline through to 17 weeks
Ganaxolone PK parameters at steady-state in participants receiving ganaxolone doses up to 63 mg/kg/day.
時間枠:Baseline through to 17 weeks

Non-compartmental-like steady-state PK parameters derived from population PK modelling and simulation: swing [(Cmax-Cmin)/Cmin])

Baseline through to 17 weeks
Activity of ganaxolone as adjunctive therapy for the treatment of primary seizures at the end of the 17-week treatment period (Part A)
時間枠:Baseline through to 17 weeks

Percent change from baseline in 28-day primary seizure frequency during the treatment period relative to the 4-week prospective Baseline Phase

Baseline through to 17 weeks
Activity of ganaxolone as adjunctive therapy for the treatment of primary seizures at the end of the 17-week treatment period (Part A)
時間枠:Baseline through to 17 weeks

Percentage of participants experiencing ≥50% reduction in the 28-day primary seizure frequency compared to the 4-week baseline

Baseline through to 17 weeks
Activity of ganaxolone as adjunctive therapy for the treatment of primary seizures at the end of the 17-week treatment period (Part A)
時間枠:Baseline through to 17 weeks

Percent change in seizures by primary seizure type

Baseline through to 17 weeks
Activity of ganaxolone as adjunctive therapy for the treatment of primary seizures at the end of the 17-week treatment period (Part A)
時間枠:Baseline through to 17 weeks

Percent change in primary seizure-free days

Baseline through to 17 weeks
Activity of ganaxolone as adjunctive therapy for the treatment of primary seizures at the end of the 17-week treatment period (Part A)
時間枠:Baseline through to 17 weeks

Clinical Global Impression of Improvement (CGI-I); 7-point Likert scale, higher scores mean a worse outcome

Baseline through to 17 weeks
Activity of ganaxolone as adjunctive therapy for the treatment of primary seizures at the end of the 17-week treatment period (Part A)
時間枠:Baseline through to 17 weeks

Caregiver Global Impression of Change in Seizure Intensity/Duration (CGI-CSID); 7-point Likert scale, higher scores mean a worse outcome

Baseline through to 17 weeks
Activity of ganaxolone as adjunctive therapy for the treatment of primary seizures at the end of the 52-week treatment period (Part B)
時間枠:Baseline through to 52 weeks

Percent change from baseline in 28-day primary seizure frequency during the treatment period relative to the 4-week prospective Baseline Phase

Baseline through to 52 weeks
Activity of ganaxolone as adjunctive therapy for the treatment of primary seizures at the end of the 52-week treatment period (Part B)
時間枠:Baseline through to 52 weeks

Percentage of participants experiencing ≥50% reduction in the 28-day primary seizure frequency compared to the 4-week baseline

Baseline through to 52 weeks
Activity of ganaxolone as adjunctive therapy for the treatment of primary seizures at the end of the 52-week treatment period (Part B)
時間枠:Baseline through to 52 weeks

Percent change in seizures by primary seizure type

Baseline through to 52 weeks
Activity of ganaxolone as adjunctive therapy for the treatment of primary seizures at the end of the 52-week treatment period (Part B)
時間枠:Baseline through to 52 weeks

Percent change in primary seizure-free days

Baseline through to 52 weeks
Activity of ganaxolone as adjunctive therapy for the treatment of primary seizures at the end of the 52-week treatment period (Part B)
時間枠:Baseline through to 52 weeks

Clinical Global Impression of Improvement (CGI-I); 7-point Likert scale, higher scores mean a worse outcome

Baseline through to 52 weeks
Activity of ganaxolone as adjunctive therapy for the treatment of primary seizures at the end of the 52-week treatment period (Part B)
時間枠:Baseline through to 52 weeks

Caregiver Global Impression of Change in Seizure Intensity/Duration (CGI-CSID); 7-point Likert scale, higher scores mean a worse outcome

Baseline through to 52 weeks

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2027年3月1日

一次修了 (推定)

2029年12月1日

研究の完了 (推定)

2029年12月1日

試験登録日

最初に提出

2022年1月27日

QC基準を満たした最初の提出物

2022年2月18日

最初の投稿 (実際)

2022年2月21日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月4日

QC基準を満たした最後の更新が送信されました

2026年10月30日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 1042-CDD-3002
  • 2026-528611-26-00 (Ctis)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する